abobotulinumtoxinA

12/01/2001 - "Although individual dose titration and muscle selection is desirable, this study demonstrated that a dose of 500 units of Dysport injected into clinically identified neck muscles without electromyographic guidance is safe and effective in the treatment of patients with the major clinical types of cervical dystonia."
01/01/2002 - "Our findings suggest that low-dose treatment of cervical dystonia with Dysport may be clinically effective during maintenance therapy, at least for a limited period of time. "
08/01/1995 - "We conclude that a dosage of 200-400 mouse units BTA (Dysport) may also be effective in the treatment of cervical dystonia, but with fewer side effects. "
01/01/2001 - "Several studies have shown that 500 units Dysport are safe and effective in the treatment of cervical dystonia. "
07/01/2005 - "This multicenter, double-blind, randomized, controlled trial assessed the safety and efficacy of Dysport in cervical dystonia patients in the United States. "

01/01/2015 - "Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis."
08/01/2014 - "Comparison of intradermal injection with iontophoresis of abobotulinum toxin A for the treatment of primary axillary hyperhidrosis: a randomized, controlled trial."
05/01/2003 - "This French study confirms the efficacy of botulinum toxin A in the treatment of axillary and palmar hyperhidrosis with relatively low doses (100 U of Dysport per armpit and 250 U per palm). "
09/01/2011 - "Both Botox and Dysport led to a similar perceived reduction of sweating in the treatment of primary axillary hyperhidrosis when a conversion factor of 1:3 was used. "
09/01/2011 - "A patient with primary axillary hyperhidrosis was treated with 100 units of Botox into the right axilla and 300 units of Dysport into the left axilla. "

01/01/2014 - "Patients treated with abobotulinumtoxinA reported significantly greater improvements in Physical Functioning, Role Physical, Bodily Pain, General Health and Role Emotional domains than placebo patients (p≤0.03 for all). "
11/01/2006 - "Compared with placebo, Dysport resulted in a significantly greater change from baseline in pain intensity during weeks 5-8 (p<0.05), and significantly fewer days per week without pain between weeks 5 and 12 (p=0.036). "
02/18/2005 - "All doses of Dysport studied showed a significant reduction from baseline of muscle tone and pain compared to placebo. "
06/01/2012 - "We present the first split-face study investigating differences in subjective pain when using preserved and preservative-free saline as the reconstituent of choice for abobotulinumtoxinA. "
04/01/2013 - "We prospectively 62 patients were assessed with visual analogue scores (VAS) for pain on the affected side before, and 6 weeks after botulinum injection(s) (50 units Dysport in up to 3 sites), and measured mouth opening in mm. Of those treated 49 (79%) showed at least some improvement (pain reduced by more than 25%). "

06/01/1998 - "This study is the first to show, in detail, the long term results of treatments of hemifacial spasm with Dysport. "
06/01/1998 - "To describe the long term efficacy and side effects of the treatment of hemifacial spasm with Dysport and to evaluate two different sites of injection to hopefully reduce side effects. "
06/01/2005 - "At the twelfth week after Dysport injection, it was still effective in relieving blepharospasm or hemifacial spasm. "
01/01/2015 - "Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm."
01/01/2015 - "The aim was to elucidate clinical trial efficacy, safety, and dosing practices of abobotulinumtoxinA (ABO) treatment in adult patients with blepharospasm and hemifacial spasm. "

06/01/2005 - "At the twelfth week after Dysport injection, it was still effective in relieving blepharospasm or hemifacial spasm. "
01/01/2015 - "Systematic Literature Review of AbobotulinumtoxinA in Clinical Trials for Blepharospasm and Hemifacial Spasm."
01/01/2015 - "The aim was to elucidate clinical trial efficacy, safety, and dosing practices of abobotulinumtoxinA (ABO) treatment in adult patients with blepharospasm and hemifacial spasm. "
09/01/2006 - "The costs of essential blepharospasm and hemifacial spasm treatment with Dysport are high, mainly because of the toxin price. "
09/01/2006 - "4- Dysport treatment is successful in both essential blepharospasm and hemifacial spasm. "